Loading
BioNTech SE, a biotechnology firm, specializes in the creation and marketing of immune-based treatments for malignancies and various infectious diseases. A significant part of its oncology pipeline includes the FixVac cancer vaccine program, which features several candidates in different phases of clinical development: BNT111 is in Phase 2 for advanced melanoma. BNT112 has reached Phase 1/2a for prostate cancer. BNT113 is undergoing Phase 2 investigation for HPV-positive head and neck cancers. BNT114 is in Phase 1 for triple-negative breast cancer. BNT115 is also in Phase 1, targeting ovarian cancer. BNT116 is a preclinical candidate for non-small cell lung cancer. The company also pioneers personalized therapies that target neoantigens, such as Autogene cevumeran (BNT122), which is in Phase 2 for first-line melanoma and Phase 1a/1b for a range of solid tumors. Furthermore, its pipeline includes an mRNA-based intratumoral immunotherapy, SAR441000, currently in Phase 1 for solid tumors, as well as BNT141 and BNT142, also in Phase 1 for multiple solid tumors. BioNTech's portfolio extends to RiboCytokine therapies (BNT151, BNT152, and BNT153) aimed at solid tumors, and cutting-edge chimeric antigen receptor T-cell (CAR T-cell) immunotherapies like BNT211 for various solid tumors and BNT221 for other types of cancer. Immune checkpoint modulators, specifically GEN1046 and GEN1042, are also under Phase 1/2 clinical investigation for solid tumors. Beyond these, the firm is developing BNT321, an IgG1 monoclonal antibody in Phase 2 for pancreatic cancer, and BNT411, a small molecule immunomodulator candidate for solid tumors. Its broader scope encompasses preventative vaccines for illnesses like COVID-19 and Influenza, additional immunotherapies for infectious diseases, and protein replacement therapies designed for rare conditions. To advance its extensive pipeline, BioNTech has forged strategic partnerships with major pharmaceutical and biotechnology firms, including Genentech, Sanofi S.A., Genmab A/S, Pfizer Inc., Shanghai Fosun Pharmaceutical (Group) Co., Ltd., and Regeneron Pharmaceuticals, Inc. Established in 2008, BioNTech SE maintains its principal operations in Mainz, Germany.
Previous close
$103.76
+$0.88 · +0.86%
Regular session · ET · Market data may be delayed.
BioNTech SE, a biotechnology firm, specializes in the creation and marketing of immune-based treatments for malignancies and various infectious diseases. A significant part of its oncology pipeline includes the FixVac cancer vaccine program, which features several candidates in different phases of clinical development: BNT111 is in Phase 2 for advanced melanoma. BNT112 has reached Phase 1/2a for prostate cancer. BNT113 is undergoing Phase 2 investigation for HPV-positive head and neck cancers. BNT114 is in Phase 1 for triple-negative breast cancer. BNT115 is also in Phase 1, targeting ovarian cancer. BNT116 is a preclinical candidate for non-small cell lung cancer. The company also pioneers personalized therapies that target neoantigens, such as Autogene cevumeran (BNT122), which is in Phase 2 for first-line melanoma and Phase 1a/1b for a range of solid tumors. Furthermore, its pipeline includes an mRNA-based intratumoral immunotherapy, SAR441000, currently in Phase 1 for solid tumors, as well as BNT141 and BNT142, also in Phase 1 for multiple solid tumors. BioNTech's portfolio extends to RiboCytokine therapies (BNT151, BNT152, and BNT153) aimed at solid tumors, and cutting-edge chimeric antigen receptor T-cell (CAR T-cell) immunotherapies like BNT211 for various solid tumors and BNT221 for other types of cancer. Immune checkpoint modulators, specifically GEN1046 and GEN1042, are also under Phase 1/2 clinical investigation for solid tumors. Beyond these, the firm is developing BNT321, an IgG1 monoclonal antibody in Phase 2 for pancreatic cancer, and BNT411, a small molecule immunomodulator candidate for solid tumors. Its broader scope encompasses preventative vaccines for illnesses like COVID-19 and Influenza, additional immunotherapies for infectious diseases, and protein replacement therapies designed for rare conditions. To advance its extensive pipeline, BioNTech has forged strategic partnerships with major pharmaceutical and biotechnology firms, including Genentech, Sanofi S.A., Genmab A/S, Pfizer Inc., Shanghai Fosun Pharmaceutical (Group) Co., Ltd., and Regeneron Pharmaceuticals, Inc. Established in 2008, BioNTech SE maintains its principal operations in Mainz, Germany.
Day range
Current $103.76
52-week range
Current $103.76
Regular session · ET · Market data may be delayed.
AI-powered factor overview
GoAI Score
Hold
Wait — insufficient conviction to act
Valuation
49
Fair Value
Sentiment
66
Bullish
Risk
41
Elevated Risk
Momentum
38
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
BioNTech SE, a biotechnology firm, specializes in the creation and marketing of immune-based treatments for malignancies and various infectious diseases. A significant part of its oncology pipeline includes the FixVac cancer vaccine program, which features several candidates in different phases of clinical development: BNT111 is in Phase 2 for advanced melanoma. BNT112 has reached Phase 1/2a for prostate cancer. BNT113 is undergoing Phase 2 investigation for HPV-positive head and neck cancers. BNT114 is in Phase 1 for triple-negative breast cancer. BNT115 is also in Phase 1, targeting ovarian cancer. BNT116 is a preclinical candidate for non-small cell lung cancer. The company also pioneers personalized therapies that target neoantigens, such as Autogene cevumeran (BNT122), which is in Phase 2 for first-line melanoma and Phase 1a/1b for a range of solid tumors. Furthermore, its pipeline includes an mRNA-based intratumoral immunotherapy, SAR441000, currently in Phase 1 for solid tumors, as well as BNT141 and BNT142, also in Phase 1 for multiple solid tumors. BioNTech's portfolio extends to RiboCytokine therapies (BNT151, BNT152, and BNT153) aimed at solid tumors, and cutting-edge chimeric antigen receptor T-cell (CAR T-cell) immunotherapies like BNT211 for various solid tumors and BNT221 for other types of cancer. Immune checkpoint modulators, specifically GEN1046 and GEN1042, are also under Phase 1/2 clinical investigation for solid tumors. Beyond these, the firm is developing BNT321, an IgG1 monoclonal antibody in Phase 2 for pancreatic cancer, and BNT411, a small molecule immunomodulator candidate for solid tumors. Its broader scope encompasses preventative vaccines for illnesses like COVID-19 and Influenza, additional immunotherapies for infectious diseases, and protein replacement therapies designed for rare conditions. To advance its extensive pipeline, BioNTech has forged strategic partnerships with major pharmaceutical and biotechnology firms, including Genentech, Sanofi S.A., Genmab A/S, Pfizer Inc., Shanghai Fosun Pharmaceutical (Group) Co., Ltd., and Regeneron Pharmaceuticals, Inc. Established in 2008, BioNTech SE maintains its principal operations in Mainz, Germany.
Day range
Current $103.76
52-week range
Current $103.76
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (EUR) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 2.76B EUR | 2.75B EUR | 3.82B EUR | 17.31B EUR | 18.98B EUR |
| Cost of goods sold | 616.47M EUR | 541.3M EUR | 599.8M EUR | 3B EUR | 2.91B EUR |
| Gross profit | 2.14B EUR | 2.21B EUR | 3.22B EUR | 14.32B EUR | 16.07B EUR |
| Research and development | 2.02B EUR | 2.25B EUR | 1.78B EUR | 1.54B EUR | 949.2M EUR |
| Selling, general, and administrative | 698.2M EUR | 599M EUR | 557.7M EUR | 541.2M EUR | 327.2M EUR |
| Operating expenses | 2.76B EUR | 3.52B EUR | 2.53B EUR | 1.67B EUR | 781.4M EUR |
| Interest income | 252.24M EUR | — | 351.31M EUR | 47.37M EUR | 1.56M EUR |
| Interest expense | 13.64M EUR | 13.16M EUR | 7.76M EUR | 15.82M EUR | 5.63M EUR |
| Depreciation and amortization | 367.69M EUR | 298M EUR | 183.4M EUR | 123.3M EUR | 75.2M EUR |
| Operating income | −623.87M EUR | −1.31B EUR | 690.4M EUR | 12.64B EUR | 15.28B EUR |
| Net income | −1.09B EUR | −665.3M EUR | 930.3M EUR | 9.43B EUR | 10.29B EUR |
Company facts updated Sep 6, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$129.57
24.87% upside| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
Dividend | Jun 2, 2022 | $2.111Irregular | Jun 3, 2022 | Jun 17, 2022 |
Ex-dividend Jun 2, 2022
$2.111
Irregular
Record Jun 3, 2022 · Payment Jun 17, 2022
Funds reporting this stock among their holdings, ordered by reported position size.
First Trust NYSE Arca Biotechnology Index FundFBT101.81M3.41%2.95B USD0.55%$270.93-1.04%
iShares Biotechnology ETFIBB69.22M0.66%10.72B USD0.44%$211.92-0.88%
Schwab Fundamental International Large Company Index ETFFNDF27.44M0.10%26B USD0.25%$56.31+0.23%
State Street SPDR Portfolio Developed World ex-US ETFSPDW10.07M0.02%42.37B USD0.03%$52.31+0.40%
iShares Genomics Immunology and Healthcare ETFIDNA8.89M3.41%262.44M USD0.47%$39.77-1.29%
VanEck Biotech ETFBBH8.84M1.79%482.23M USD0.35%$241.12-1.06%
JPMorgan BetaBuilders Europe ETFBBEU7.57M0.08%9.45B USD0.09%$80.01+0.01%
Invesco NASDAQ Next Gen 100 ETFQQQJ7.11M0.59%1.2B USD0.15%$45.26-0.20%First Trust NYSE Arca Biotechnology Index FundFBTiShares Biotechnology ETFIBBSchwab Fundamental International Large Company Index ETFFNDFState Street SPDR Portfolio Developed World ex-US ETFSPDWiShares Genomics Immunology and Healthcare ETFIDNAVanEck Biotech ETFBBHJPMorgan BetaBuilders Europe ETFBBEUInvesco NASDAQ Next Gen 100 ETFQQQJAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
